Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys induction dosing plus higher-dose Copegus in treatment-naive genotype 1 chronic hepatitis C
2005-005507-41Phase 4Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of interferon alfa and ribavirin in hepatitis C virus infection (4 arms), sponsored by Roche. Primary endpoint: Sustained virological response at 24 weeks after treatment. Started Sep 2006; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-005507-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005507-41.